Click here to close now.



Welcome!

News Feed Item

PharmaPoint: Crohn's Disease - India Drug Forecast and Market Analysis to 2022

NEW YORK, April 9, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

 

PharmaPoint: Crohn's Disease - India Drug Forecast and Market Analysis to 2022

http://www.reportlinker.com/p02063644/PharmaPoint-Crohn's-Disease---India-Drug-Forecast-and-Market-Analysis-to-2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication

 

PharmaPoint: Crohn's Disease - India Drug Forecast and Market Analysis to 2022

 

Summary

 

The Crohn's disease (CD) market is currently very dynamic, with novel biologic therapies on the horizon. These compounds will challenge the current biologics in an attempt to dislodge the stronghold of the TNF inhibitors, as they aim to tap into the lucrative portion of the CD therapeutics market. If their promising safety and efficacy profiles translate to clinical practice once they enter the market, their launch will be to the detriment of the existing market leaders, Remicade (infliximab) and Humira (adalimumab).The loss of patent protection of the anti-TNF marketed brands will allow for the emergence of biosimilars, such as Hospira's Inflectra (infliximab) a Remicade biosimilar. Focusing on country dynamics, Canada and the emerging markets of China and India will also play a key role in driving growth in the long term, with each market forecast to post positive Compound Annual Growth Rates (CAGRs) from 2012 to 2022, primarily due to the anticipated strong uptake of Remicade over the forecast period.

 

For the treatment of CD, Indian physicians rely heavily on non-pharmacological methods, such as dietary recommendations, and for pharmacologic therapy, they use generic products within the corticosteroids and 5-ASAs. GlobalData's physician survey showed that these drugs are the mainstay of treatment for mild to moderate CD in India, as well as at earlier lines of therapy for severe disease. While Indian physicians commonly prescribe domestic generics and biosimilars, our primary research revealed that biosimilars were not readily available to those with CD.

 

Scope

 

- Overview of Crohn's disease including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.

- Detailed information on the key drugs in India including product description, safety and efficacy profiles as well as a SWOT analysis.

- Sales forecast for the top drugs in India from 2012-2022.

- Analysis of the impact of key events as well the drivers and restraints affecting the India Crohn's disease market.

 

Reasons to buy

 

- Understand and capitalize by identifying products that are most likely to ensure a robust return.

- Stay ahead of the competition by understanding the changing competitive landscape for Crohn's disease.

- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential.

- Make more informed business decisions from insightful and in-depth analysis of drug performance.

- Obtain sales forecast for drugs from 2012-2022 in India.

1 Table of Contents

2 Introduction 9

2.1 Catalyst 9

2.2 Related Reports 10

2.3 Upcoming Related Reports 11

3 Disease Overview 12

3.1 Etiology and Pathophysiology 12

3.1.1 Etiology 12

3.1.2 Pathophysiology 12

3.2 Symptoms 16

3.3 Prognosis 17

3.4 Quality of Life 18

4 Disease Management 19

4.1 Treatment Overview 20

4.2 India 25

4.2.1 Diagnosis 25

4.2.2 Clinical Practice 25

5 Competitive Assessment 27

5.1 Overview 27

5.2 Strategic Competitor Assessment 28

5.3 Product Profiles - Major Brands 29

5.3.1 Remicade (infliximab) 29

5.3.2 Other Marketed Products 35

6 Opportunity and Unmet Need 36

6.1 Overview 36

6.2 Physicians Desire Biomarkers That Will Allow a Personalized Treatment Approach 37

6.3 More Therapies for Anti-TNF-Refractory Patients 38

6.4 Unmet Needs Gap Analysis 39

6.5 Targeted Therapies 40

6.6 Predictive Tools for Early Diagnosis and Treatment 41

7 Pipeline Assessment 42

7.1 Overview 42

7.2 Promising Drugs in Clinical Development 42

7.3 Other Late-Stage Pipeline Products 44

7.3.1 Cx601 44

7.3.2 RHB-104 (clarithromycin + clofazimine + rifabutin) 46

8 Market Outlook 51

8.1 Global Markets 51

8.1.1 Drivers and Barriers - Global Issues 51

9 India 56

9.1 Forecast 56

9.2 Key Events 58

9.3 Drivers and Barriers 59

9.3.1 Driver: Continued investment in the national healthcare system and services 59

9.3.2 Driver: Sizeable CD patient population that will increase over the coming decade 59

9.3.3 Barrier: Loose intellectual property policies present a major challenge for developers with novel drugs 60

9.3.4 Barrier: Limited access to and the high price point of CD therapies, coupled with many Indians' belief in traditional medicine, negatively impacts branded drug sales 60

9.3.5 Barrier: Downward pricing pressure limits drug sales growth 61

10 Appendix 62

10.1 Bibliography 62

10.2 Abbreviations 67

10.3 Methodology 71

10.4 Forecasting Methodology 71

10.4.1 Diagnosed CD Patients 71

10.4.2 Percent Drug-Treated Patients 72

10.4.3 Drugs Included in Each Therapeutic Class 72

10.4.4 General Pricing Assumptions 72

10.4.5 Individual Drug Assumptions 74

10.4.6 Generic Erosion 74

10.5 Physicians and Specialists Included in This Study 75

10.6 Primary Research - Prescriber Survey 76

10.7 About the Authors 77

10.7.1 Author/Reviewer 77

10.7.2 Global Head of Healthcare 77

10.8 About GlobalData 78

10.9 Disclaimer 78

 

1.1 List of Tables

 

Table 1: Symptoms of CD 17

Table 2: Treatment Guidelines for CD 21

Table 3: Most Commonly Prescribed Drugs for CD in the Global Markets by Disease Severity, 2013 23

Table 4: Leading Branded Drugs Used to Treat CD 29

Table 5: Product Profile - Remicade 31

Table 6: Remicade SWOT Analysis, 2013 34

Table 7: Summary of the Minor Therapeutic Classes in CD, 2013 35

Table 8: Overall Unmet Needs in CD - Current Level of Attainment 37

Table 9: Clinical Unmet Needs in CD - Gap Analysis, 2013 40

Table 10: Promising Drugs in Clinical Development for CD - Pipeline Phase, 2013 42

Table 11: Comparison of Therapeutic Classes in Development for CD, 2013 43

Table 12: Product Profile - Cx601 45

Table 13: Cx601 SWOT Analysis, 2013 46

Table 14: Product Profile - RHB-104 48

Table 15: RHB-104 SWOT Analysis, 2013 50

Table 16: Global CD Market - Drivers and Barriers, 2012-2022 51

Table 17: Sales Forecasts ($) for CD in India, 2012-2022 57

Table 18: Key Events Impacting Sales for CD in India, 2012-2022 58

Table 19: CD Market in India - Drivers and Barriers, 2012-2022 59

Table 20: Physicians Surveyed, By Country 76

 

1.2 List of Figures

 

Figure 1: Mucosa of the Bowel in a Healthy Individual (Left) and a Patient With CD (Right) 13

Figure 2: Potential Biologic Drug Targets for CD 16

Figure 3: Patient Care Path for CD 22

Figure 4: Competitive Assessment of Late-Stage Pipeline Agents in CD, 2012-2022 43

Figure 5: Sales for CD in India by Drug Class, 2012-2022 58

 

 

To order this report: PharmaPoint: Crohn's Disease - India Drug Forecast and Market Analysis to 2022

http://www.reportlinker.com/p02063644/PharmaPoint-Crohn's-Disease---India-Drug-Forecast-and-Market-Analysis-to-2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication

Contact Clare: [email protected]
US:(339) 368 6001
Intl:+1 339 368 6001

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
As enterprises work to take advantage of Big Data technologies, they frequently become distracted by product-level decisions. In most new Big Data builds this approach is completely counter-productive: it presupposes tools that may not be a fit for development teams, forces IT to take on the burden of evaluating and maintaining unfamiliar technology, and represents a major up-front expense. In his session at @BigDataExpo at @ThingsExpo, Andrew Warfield, CTO and Co-Founder of Coho Data, will dis...
SYS-CON Events announced today that Fusion, a leading provider of cloud services, will exhibit at SYS-CON's 18th International Cloud Expo®, which will take place on June 7-9, 2016, at the Javits Center in New York City, NY. Fusion, a leading provider of integrated cloud solutions to small, medium and large businesses, is the industry's single source for the cloud. Fusion's advanced, proprietary cloud service platform enables the integration of leading edge solutions in the cloud, including clou...
As someone who has been dedicated to automation and Application Release Automation (ARA) technology for almost six years now, one of the most common questions I get asked regards Platform-as-a-Service (PaaS). Specifically, people want to know whether release automation is still needed when a PaaS is in place, and why. Isn't that what a PaaS provides? A solution to the deployment and runtime challenges of an application? Why would anyone using a PaaS then need an automation engine with workflow ...
With the Apple Watch making its way onto wrists all over the world, it’s only a matter of time before it becomes a staple in the workplace. In fact, Forrester reported that 68 percent of technology and business decision-makers characterize wearables as a top priority for 2015. Recognizing their business value early on, FinancialForce.com was the first to bring ERP to wearables, helping streamline communication across front and back office functions. In his session at @ThingsExpo, Kevin Roberts...
SYS-CON Events announced today that Commvault, a global leader in enterprise data protection and information management, has been named “Bronze Sponsor” of SYS-CON's 18th International Cloud Expo, which will take place on June 7–9, 2016, at the Javits Center in New York City, NY, and the 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Commvault is a leading provider of data protection and information management...
Your business relies on your applications and your employees to stay in business. Whether you develop apps or manage business critical apps that help fuel your business, what happens when users experience sluggish performance? You and all technical teams across the organization – application, network, operations, among others, as well as, those outside the organization, like ISPs and third-party providers – are called in to solve the problem.
SYS-CON Events announced today that Alert Logic, Inc., the leading provider of Security-as-a-Service solutions for the cloud, will exhibit at SYS-CON's 18th International Cloud Expo®, which will take place on June 7-9, 2016, at the Javits Center in New York City, NY. Alert Logic, Inc., provides Security-as-a-Service for on-premises, cloud, and hybrid infrastructures, delivering deep security insight and continuous protection for customers at a lower cost than traditional security solutions. Ful...
@DevOpsSummit taking place June 7-9, 2016 at Javits Center, New York City, and Nov 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA, is co-located with the 18th International @CloudExpo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world. @DevOpsSummit at Cloud Expo New York Call for Papers is now open.
SYS-CON Events announced today that VAI, a leading ERP software provider, will exhibit at SYS-CON's 18th International Cloud Expo®, which will take place on June 7-9, 2016, at the Javits Center in New York City, NY. VAI (Vormittag Associates, Inc.) is a leading independent mid-market ERP software developer renowned for its flexible solutions and ability to automate critical business functions for the distribution, manufacturing, specialty retail and service sectors. An IBM Premier Business Part...
Let’s face it, embracing new storage technologies, capabilities and upgrading to new hardware often adds complexity and increases costs. In his session at 18th Cloud Expo, Seth Oxenhorn, Vice President of Business Development & Alliances at FalconStor, will discuss how a truly heterogeneous software-defined storage approach can add value to legacy platforms and heterogeneous environments. The result reduces complexity, significantly lowers cost, and provides IT organizations with improved effi...
SYS-CON Events announced today that Catchpoint Systems, Inc., a provider of innovative web and infrastructure monitoring solutions, has been named “Silver Sponsor” of SYS-CON's DevOps Summit at 18th Cloud Expo New York, which will take place June 7-9, 2016, at the Javits Center in New York City, NY. Catchpoint is a leading Digital Performance Analytics company that provides unparalleled insight into customer-critical services to help consistently deliver an amazing customer experience. Designed...
SYS-CON Events announced today that Pythian, a global IT services company specializing in helping companies adopt disruptive technologies to optimize revenue-generating systems, has been named “Bronze Sponsor” of SYS-CON's 18th Cloud Expo, which will take place on June 7-9, 2015 at the Javits Center in New York, New York. Founded in 1997, Pythian is a global IT services company that helps companies compete by adopting disruptive technologies such as cloud, Big Data, advanced analytics, and DevO...
SYS-CON Events announced today that Men & Mice, the leading global provider of DNS, DHCP and IP address management overlay solutions, will exhibit at SYS-CON's 18th International Cloud Expo®, which will take place on June 7-9, 2016, at the Javits Center in New York City, NY. The Men & Mice Suite overlay solution is already known for its powerful application in heterogeneous operating environments, enabling enterprises to scale without fuss. Building on a solid range of diverse platform support,...
Cognitive Computing is becoming the foundation for a new generation of solutions that have the potential to transform business. Unlike traditional approaches to building solutions, a cognitive computing approach allows the data to help determine the way applications are designed. This contrasts with conventional software development that begins with defining logic based on the current way a business operates. In her session at 18th Cloud Expo, Judith S. Hurwitz, President and CEO of Hurwitz & ...
One of the bewildering things about DevOps is integrating the massive toolchain including the dozens of new tools that seem to crop up every year. Part of DevOps is Continuous Delivery and having a complex toolchain can add additional integration and setup to your developer environment. In his session at @DevOpsSummit at 18th Cloud Expo, Miko Matsumura, Chief Marketing Officer of Gradle Inc., will discuss which tools to use in a developer stack, how to provision the toolchain to minimize onboa...